Last checked at 2 Oct 2007 16:28
PROTEOME SCIENCES plc ("Proteome Sciences" or "the Company")
2 October 2007Retirement of Mr. A. J. Green
Proteome Sciences plc ("Proteome Sciences") today announces that as indicated in its Interim Statement announced on Friday 28th September, 2007, Mr. A.J. Green has today retired from the company and has therefore resigned as a Director of the Company.
We would like to take this opportunity to thank him for his contribution and to wish him well in the future.
Ends Notes to editors:
Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has discovered blood biomarkers principally for stroke, vCJD, BSE, brain damage, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, oncology and cardiovascular conditions.
In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP‚® (Proteome Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification and validation of potential biomarkers and drug targets, including specialisation in membrane proteins and protein phosphorylation.
The Company has developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer‚®, PST‚®, qPST¢â€ž¢ and TMT‚®. Proteome Sciences has patent allowances in the major global jurisdictions for isobaric tandem mass tags (TMT ‚®) for the manufacture and use of any type of isobaric mass tags.
Commercialisation is actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP‚®.
Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and Frankfurt Innovations Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its corporate and business development staff, and has collaborative research agreements with leading academic institutes. The Company is listed on the Alternative Investment Market.
For further information please visit www.proteomics.com.
Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Email: christopher.pearce@proteomics.com
James Malthouse, Finance Director
Email: james.malthouse@proteomics.com
Tel: +44 (0)1932 865065 Public RelationsIKON Associates Adrian Shaw Tel: +44 (0)1483 535102 Mobile: +44 (0)797 9900733
Email: adrian@ikonassociates.com
Coast CommunicationsMatt BaldwinTel: +44 (0)1233 503200Mobile: +44 (0)7930 439739
Email: matt@coastcommunications.com
Nominated Adviser
Landsbanki Securities (UK) Limited
Thilo Hoffman - Tel: +44 (0)20 7426 9000
PROTEOME SCIENCES PLC